We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Stakeholders Urge Tweaks in Draft Guidance on Pregnant Trial Subjects
Stakeholders Urge Tweaks in Draft Guidance on Pregnant Trial Subjects
The FDA’s draft guidance on inclusion of pregnant women in clinical trials needs some fine tuning, according to stakeholders, including more clarity on non-adherence to therapies.
To View This Article:
Login
Subscribe To International Pharmaceutical Regulatory Monitor